Automatisering av förpackningsprocess

Abstract: The production rate at Octapharma AB, Stockholm is about to increase. The factory will be able to handle 1000 tonne human plasma a year instated of today’s capacity of 350 tonne. Today product packaging is carried out manually, which will be highly inefficient in a larger production scale. To analyze the automation demands a lot of pre-studies. Octapharma AB has given us the opportunity to do a pre-study for a future change within the packing department. The aim of the degree project is: • To study the total material flow for packaging of pharmaceuticals. • Automation of present manually packed pharmaceutical. • Determent if present equipment can be used in automation. • Increase the packaging and controls efficiency. The objective of the degree project is: • Find appropriate suggestions for new machines in pharmaceutical product packaging. • To find a suitable placement for machines in allotted area. • Achieve a short and efficient process time. • Suggest a material flow. • The report shall contain a Swedish user requirements specification. High quality products are very important in pharmaceutical industry and failure is not an option. Packaging demands accuracy. There might be a risk of error in human control performances with devastating consequences if failure occurs. Products may not be packed with the wrong leaflet or stamped with the wrong label. The degree project results in a pre-study to an upcoming project for Octapharma AB. The report contains a Swedish and an English user requirements specification (URS). The report also contains a proposition of logistic on the packaging department. The logistics includes machine placements, a storage and handling of order documentation. Other materials concerning the project are attached as appendixes with the final report. Highly important advantages with the project are: • Considerable capacity increase. • Possible future extension of the packaging line. A two gears secondary bulk packaging line can be connected to the existing machines. • The quality control will improve and fulfil GMP-requirements. • Octapharma AB will be able to increase there production capacity considerably.